September 19, 2025

How HIV enters the genome – Researchers identify previously unknown mechanism

How HIV enters the genome – Researchers identify previously unknown mechanism

Researchers at the German Center for Infection Research (DZIF) at Heidelberg Faculty of Medicine have decoded a previously unknown mechanism by which HIV-1 selects its integration targets in the human genome. A research team led by DZIF scientist Dr. Marina Lusic identified RNA:DNA hybrids (R-loops) as molecular signposts for the virus. These findings reveal a key vulnerability in the life cycle of HIV-1. The results, published in the renowned journal Nature Microbiology, provide new therapeutic approaches for specifically controlling HIV reservoirs in the body. This has been one of the biggest obstacles to long-term or curative HIV therapies.

Press release by the German Center for Infection Research (DZIF): Thanks to antiretroviral therapy, people living with HIV can lead almost normal lives. Antiretroviral drugs prevent the virus from multiplying, but must be taken daily for life. However, any interruption in treatment—due to limited access, supply disruptions, or adherence challenges—can result in rapid viral rebound and, more worryingly, the emergence of drug-resistant HIV variants.

The HIV virus primarily infects cells of the immune system, anchoring its genetic material in T cells in particular. Once integrated, these viral sequences create lifelong reservoir of infection. The HIV-1 integrase enzyme is responsible for inserting the virus into the host genome, forcing cells to produce new viruses and enabling the ongoing infection process. “Until now, it has been not entirely clear how HIV-1 integrase selects its integration targets in the genome. A deeper understanding of this process is crucial for developing new treatment strategies and tackling the persistent viral reservoirs that cannot be eliminated by existing therapies,” says Dr. Marina Lusic, DZIF scientist at the Center for Integrative Infectious Disease Research (CIID) at Heidelberg University Hospital, who led the study.

RNA:DNA hybrids as signposts for virus integration   

The research team was able to prove that HIV-1 does not randomly invade the genome, but uses specific signposts: so-called RNA:DNA hybrids or “R-loops”, which mainly occur in non-coding regions of active genes. The researchers mapped these structures in human immune cells and demonstrated that the viral integrase docks precisely at these locations. “The virus follows these structures like signposts on a map and thus finds the appropriate integration sites,” explains Dr. Carlotta Penzo, senior postdoctoral researcher in Dr. Marina Lusic’s team and first author of the study. “Another important result of our investigation is that a specific cellular partner, the enzyme Aquarius, helps the virus in R-loop recognition, enabling HIV-1 insertion into RNA:DNA hybrids.”

The splicing enzyme RNA helicase Aquarius (AQR) plays a key role in this process. It acts as a kind of door opener, binding to HIV-1 integrase and promoting integration by unwinding the R-loops. “Our results show that removing AQR significantly decreases the integration rate. The remaining integration events shift to R-loop-poor regions—clear evidence of the association between viral integration and AQR activity on R-loops,” says Penzo.

“This discovery opens a new avenue for HIV intervention. If we can disrupt the virus’s ability to use host RNA structures for integration, we may be able to limit or redirect where HIV hides and ultimately reduce or eliminate the need for lifelong therapy,” says Dr. Marina Lusic. “These findings are particularly significant in light of the increasing global instability in HIV care. In many regions, the continuous provision of antiretroviral therapies is not guaranteed—with the result that interruptions significantly increase the risk of treatment failure and the spread of resistant virus variants.”

The results reveal previously unknown targets for combating HIV. In the long term, the identified R-loop/Aquarius mechanism could help to specifically target HIV reservoirs in the body that existing therapies cannot eliminate—and thus point the way to new, effective, and potentially curative forms of treatment.

Funding and international collaboration

This study was supported by the German Center for Infection Research (Deutsches Zentrum für Infektionsforschung, DZIF) and by the German Research Foundation (DFG) through the Special Collaborative Programme SFB 1129. It was conducted through a multidisciplinary collaboration led by the group of Dr. Marina Lusic, in partnership with colleagues from the Center for Integrative Infectious Disease Research (CIID) Heidelberg, including Prof. Oliver Fackler and Prof. Hans-Georg Kräusslich. Furthermore, the study was made possible by close pan-European collaboration, with contributions from bioinformatics, structural biology and retrovirology experts at research institutions in Zagreb, Padua, London and Bordeaux.

Contact

Dr. Marina Lusic
Universitätsklinikum Heidelberg

marina.lusic@med.uni-heidelberg.de

Literature

Penzo C, Özel I, Martinovic M, Kuzman M, Glavas D, Stanic M, Reichenbach T, Müller TG, Rheinberger M, Godarzi N, Lapaillerie D, Srezovic B, dell’Oca MC, Lange LC, Sadhu L, de Castro IJ, Shytaj IL, Forcato M, Laketa V, Bicciato S, Vlahovicek K, Fackler OT, Lucic B, Pena V, Kräusslich HG, Parissi V, Lusic M. Aquarius helicase facilitates HIV-1 integration into R-loop enriched genomic regions. Nat Microbiol. 2025 Sep;10(9):2306-2322. doi: 10.1038/s41564-025-02089-2. Epub 2025 Aug 20. PMID: 40836041.

https://doi.org/10.1038/s41564-025-02089-2

Our latest News

discover more
Tailor-Made Fertilization

Tailor-Made Fertilization

Excessive fertilization in agriculture weakens crops, threatens drinking water quality, and harms the soil. Researchers at the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB are now developing an alternative fertilizer that is fully biodegradable, supplies plants exclusively with the nutrients they need, and prevents over-fertilization. More information in German below: Jahr für Jahr werden […]

Two German Cancer Awards for Researchers at Heidelberg University’s Faculty of Medicine

Two German Cancer Awards for Researchers at Heidelberg University’s Faculty of Medicine

Professor Dr. Jessica Hassel, Faculty of Medicine Heidelberg at Heidelberg University and Head of the Skin Cancer Center at Heidelberg University Hospital and the National Center for Tumor Diseases (NCT) Heidelberg, has been awarded in the category “Clinical Research.” Professor Dr. Dr. Felix Sahm, also from the Faculty of Medicine Heidelberg, Department of Neuropathology at […]

Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host disease

Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host disease

Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host disease Paris, March 31, 2026. The European Commission has granted a conditional marketing authorisation for Rezurock (belumosudil) for the treatment of chronic graft-versus-host disease (GVHD) in adults and in children aged 12 years and older with a body weight of at least 40 kg. The medicine is to […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp